Guardian Pharmacy Services, Inc.
NYSE: GRDN · HEALTHCARE · MEDICAL CARE FACILITIES
Updated 2026-04-29
Guardian Pharmacy Services, Inc. (GRDN) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for GRDN.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
GRDN historical valuation range
Where current P/E sits in GRDN's own 5Y range.
GRDN intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
GRDN valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 48.19x
P/S Ratio — History
Current: 1.67x
Is GRDN overvalued in 2026?
Guardian Pharmacy Services, Inc. (GRDN) currently trades at $37.57 per share with a market capitalization of $2,418,564,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 46/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 48.2x, above its 5-year median of 48.2x.
Looking at its own history, GRDN is currently trading more expensive than 75% of the last 5Y on P/E. This places it in the 75th percentile of its historical range, a reasonable but unremarkable position.
Our discounted cash flow model estimates GRDN's intrinsic value at $166.71 per share, against the current market price of $37.57. This implies a margin of safety of +79.25%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
Financial quality is a concern. The Piotroski F-Score of 3/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: GRDN appears richly valued on our framework, with a Smart Value Score of 46/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is GRDN overvalued in 2026?
Based on a Smart Value Score of 46/100, GRDN appears overvalued. Current price exceeds what fundamentals currently justify.
What is GRDN's fair value?
Our DCF model estimates GRDN's intrinsic value at $166.71 per share, versus the current price of $37.57. This produces a margin of safety of +79.25%.
What P/E ratio does GRDN trade at?
GRDN trades at a P/E of 48.2x on trailing twelve-month earnings, compared to its 5-year median of 48.2x.
Is GRDN a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 46/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.
How does GRDN's valuation compare to its history?
On P/E, GRDN currently sits in the 75th percentile of its own 5Y range. That is historically expensive relative to where it has traded over the period.
What is GRDN's Smart Value Score?
GRDN's Smart Value Score is 46/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.